97482-19-4 Usage
Structure
Heterocyclic amine It is an amine-containing compound with a heterocyclic structure, which includes atoms other than carbon (such as nitrogen) in its rings.
Pyrrole and pyrimidine rings
Fusion The compound features a pyrrole ring fused to a pyrimidine ring, creating a unique structure with different electronic properties.
Dihydro form
Hydrogen atoms added across the double bond In this form, two hydrogen atoms are added across the double bond in the pyrrole ring, which may influence its reactivity and properties.
Potential applications
Pharmaceuticals and medicinal chemistry This compound may exhibit biological activity and serve as a building block for the synthesis of other organic compounds, making it potentially useful in drug development and related fields.
Research interest
Reactivity and behavior of heterocyclic compounds The structure and properties of 1H-Pyrrolo[2,3-d]pyrimidin-2-amine, 5,6-dihydro(9CI) make it an interesting subject for researchers studying the behavior of heterocyclic compounds in various chemical reactions and processes.
Check Digit Verification of cas no
The CAS Registry Mumber 97482-19-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,4,8 and 2 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 97482-19:
(7*9)+(6*7)+(5*4)+(4*8)+(3*2)+(2*1)+(1*9)=174
174 % 10 = 4
So 97482-19-4 is a valid CAS Registry Number.
97482-19-4Relevant articles and documents
Compound with 2-aminopyrimidine structure as well as preparation method and purpose thereof
-
Paragraph 0168-0171, (2019/06/08)
The invention provides a compound of a 2-aminopyrimidine structure shown as a general formula (1), or a stereisomer, enantiomers or medically acceptable salt of the compound, a preparation method of the compound, a medicine composition containing the composition or a purpose of the composition. The compound shown as the general formula (1) can be used for preparing NIK kinase inhibitors, and can be used for preventing and/or treating diseases relevant to NIK kinase, particularly cancer and metabolic diseases, such as B-cell dysfunction related cancer such as multiple myeloma, lymphocyte carcinoma, diffuse large B cell lymphoma of liver cancer, hodgkin lymphoma and chronic lymphocytic leukemia, prostatic cancer, liver cancer, intestinal cancer, medicine induced liver damage, alcohol inducedliver damage, toxic induced acute liver injury, chronic liver inflammation and the like. The general formula (1) is shown in the description.
